Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02333864 · ClinicalTrials.gov registry record

POGO® Automatic Blood Glucose Monitoring System Clinical Study

A clinical trial of Diabetes Mellitus, sponsored by Intuity Medical.

Completed
Registry status
287
Enrollment target
2
Study locations

NCT02333864 is a study of Diabetes Mellitus that has completed, run by Intuity Medical. The registered enrollment target is 287 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02333864, a study of Diabetes Mellitus, has completed, sponsored by Intuity Medical.

COMPLETED
Registry status
287 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine if the POGO® system delivers accurate blood glucose readings in the hands of the lay user and assess the POGO® system accuracy when used by trained health care professionals.

Conditions Studied

Interventions

  • DEVICE POGO® BGMS

Study Locations (2)

California

  • Diablo Clinical Reasearch - Walnut Creek

Minnesota

  • Park Nicollett Institute - International Diabetes Center - Minneapolis

Trial Details

FieldValue
Enrollment Target 287 participants
Start Date 2014-12
Est. Completion 2015-03

Sponsor

Intuity Medical

2 total trials

What the Registry Record Tells You About NCT02333864

The ClinicalTrials.gov registry entry for NCT02333864 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (85% lower). The listed sponsor is Intuity Medical, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which POGO® BGMS is the first listed.

NCT02333864 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Minnesota.

Frequently Asked Questions

What is clinical trial NCT02333864 about?

NCT02333864 is a clinical study titled "POGO® Automatic Blood Glucose Monitoring System Clinical Study". The purpose of this study is to determine if the POGO® system delivers accurate blood glucose readings in the hands of the lay user and assess the POGO® system accuracy when used by trained health care professionals.

What is the current status of trial NCT02333864?

This trial is currently completed. The enrollment target is 287 participants. The study started on 2014-12. Estimated completion is 2015-03.

What conditions does trial NCT02333864 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT02333864?

The interventions under investigation include: POGO® BGMS (DEVICE).

Who is sponsoring clinical trial NCT02333864?

This trial is sponsored by Intuity Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02333864 being conducted?

This trial has 2 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.